Europe Veterinary Monoclonal Antibodies Market (2025-2030)
The Europe Veterinary Monoclonal Antibodies Market was valued at $437.49 Million in 2025 and projected to reach to $765.31 Million by 2030, representing a compound annual growth rate of 11.8%. Europe's veterinary monoclonal antibodies market is positioned for sustained expansion through 2030, supported by increasing pet ownership, rising companion animal healthcare spending, and growing awareness of advanced immunotherapies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe Veterinary Monoclonal Antibodies Market Trends and Insights
- This expansion reflects Europe's strong regulatory framework, advanced veterinary healthcare infrastructure, and increasing adoption of targeted immunotherapies across companion and livestock segments.
- Europe leads in innovation and regulatory approval timelines, positioning the region as a critical hub for monoclonal antibody development and commercialization. The 11.8% compound annual growth rate in Europe is driven by rising pet ownership, growing awareness of precision medicine in veterinary practice, and substantial investment in research and development.
- Europe's stringent quality standards and established reimbursement pathways support market penetration of advanced biologics.
- Key markets including Germany, France, and the United Kingdom are accelerating adoption of monoclonal antibody therapies for oncology, immunology, and inflammatory conditions in animals. By 2030, Europe is expected to maintain its position as a mature, high-value market with increasing competition among established pharmaceutical players and emerging biotech firms.
- Europe's commitment to animal welfare and therapeutic innovation ensures sustained demand for sophisticated veterinary immunotherapies throughout the forecast period..
Key Market Statistics
- CAGR (2025-2030) 11.8% CAGR
- Market Size, 2025 ~USD 437.49 Million
- Forecast, 2030 ~USD 765.31 Million
- Geography Europe
Europe Veterinary Monoclonal Antibodies Market Overview
Market Valuation & Growth :
Europe's veterinary monoclonal antibodies market is valued at $437.49 million in 2025, with a robust CAGR of 11.8% projected through 2030, reaching $765.31 million. This growth outpaces many global regions, driven by strong healthcare infrastructure and regulatory support.
Regulatory Leadership :
Europe's stringent regulatory framework and advanced approval pathways through the EMA create a competitive advantage for monoclonal antibody development. This environment fosters innovation while ensuring high safety and efficacy standards for veterinary therapeutics.
Segment Expansion :
Both companion animal and livestock segments are experiencing significant adoption of targeted immunotherapies across Europe. Companion animal oncology and immunological disorders drive companion segment growth, while livestock disease management fuels agricultural veterinary demand.
Innovation Hub Status :
Europe leads in veterinary monoclonal antibody innovation with major pharmaceutical and biotech companies investing in R&D facilities. Key markets like Germany, UK, and France are centers for cutting-edge therapeutic development and clinical trials.
Europe Veterinary Monoclonal Antibodies Market Dynamics
- The region's mature healthcare infrastructure and strong regulatory environment attract significant investment from global and regional players, accelerating product launches and market penetration. Key growth drivers include the rising prevalence of chronic diseases in companion animals, livestock productivity demands, and European veterinarians' adoption of precision medicine approaches.
- Strategic partnerships between pharmaceutical companies and veterinary institutions, combined with favorable reimbursement policies in several European countries, will further propel market growth and establish Europe as a global leader in veterinary monoclonal antibody therapeutics..
Related Ecosystem
Animal Health
- Polymerase Chain Reaction (PCR) Tests
- Porcine
- Immunodiagnostics
- Lateral Flow Assays
- Microarrays
- Zoetis Inc.
- Patterson Companies, Inc.
- Virbac
- Elanco Animal Health Incorporated
- BOEHRINGER INGELHEIM GMBH
Key Takeaways
- Europe's veterinary monoclonal antibodies market will grow from $437.49M (2025) to $765.31M (2030) at an 11.8% CAGR.
- Europe's advanced regulatory environment and high veterinary care standards accelerate adoption of monoclonal antibody therapies.
- Rising pet ownership and precision medicine awareness in Europe drive demand for targeted immunotherapies in companion animals.
- Europe's mature market structure supports competition among established and emerging players, fostering innovation through 2030.
Veterinary Monoclonal Antibodies Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | BEDINVETMAB (LIBRELA) (Product) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 12.4% from 2025 to 2030 |
| Largest Segment | SUBCUTANEOUS ROUTE OF ADMINISTRATION (Route Of Administration) |
| Market Size Base Year (Billions) | ~USD 1.71 (2025) |
| Revenue Forecast (Billions) | ~USD 3.06 (2030) |
| Segments Covered | Animal Type, Product, Route Of Administration, Therapy Area, End User, Animal Type 2023-2030 |
Europe Veterinary Monoclonal Antibodies Market Report Segmentation
6 segment dimensions are covered across the global market.
By Animal Type
- Canines
- Felines
- Other Animal Types
- Other Animals
By Product
- Bedinvetmab (Librela)
- Canine Parvovirus Monoclonal Antibody (Cpma)
- Frunevetmab (Solensia)
- Gilvetmab
- Lokivetmab (Cytopoint)
- Other Products
By Route Of Administration
- Intravenous (Iv) Route Of Administration
- Intravenous Route Of Administration
- Oral Route Of Administration
- Subcutaneous (Sc) Route Of Administration
- Subcutaneous Route Of Administration
By Therapy Area
- Dermatology
- Infectious Diseases
- Oncology
- Other Therapy Areas
- Pain Management
By End User
- Other End Users
- Veterinary Clinics
- Veterinary Hospitals/ Specialty Centers
- Veterinary Hospitals/Specialty Clinics
- Veterinary Research & Academic Institutes
By Animal Type 2023-2030
- Canines
- Felines
- Other Animals
EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|
| OTHER END USERS | 31.51 | 34.04 | 36.83 | 39.87 | 46.8 | 50.76 | 55.13 | 8.4 |
| VETERINARY CLINICS | 135.69 | 152.59 | 171.84 | 193.64 | 246.32 | 278.06 | 314.37 | 12.8 |
| VETERINARY HOSPITALS/SPECIALTY CLINICS | 156.84 | 174.74 | 194.97 | 217.67 | 271.78 | 303.97 | 340.47 | 11.8 |
| VETERINARY RESEARCH & ACADEMIC INSTITUTES | 27.96 | 30.74 | 33.85 | 37.29 | 45.35 | 50.06 | 55.34 | 10.3 |
| TOTAL | 351.99 | 392.11 | 437.49 | 488.47 | 610.26 | 682.85 | 765.31 | 11.8 |
REST OF EUROPE: VETERINARY MONOCLONAL ANTIBODIES MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|
| OTHER END USERS | 3.91 | 4.18 | 4.48 | 4.81 | 5.55 | 5.96 | 6.41 | 7.4 |
| VETERINARY CLINICS | 17.29 | 19.27 | 21.51 | 24.02 | 30 | 33.55 | 37.58 | 11.8 |
| VETERINARY HOSPITALS/SPECIALTY CLINICS | 19.71 | 21.76 | 24.06 | 26.61 | 32.62 | 36.14 | 40.09 | 10.8 |
| VETERINARY RESEARCH & ACADEMIC INSTITUTES | 3.49 | 3.8 | 4.15 | 4.53 | 5.41 | 5.92 | 6.48 | 9.3 |
| TOTAL | 44.39 | 49.01 | 54.2 | 59.97 | 73.57 | 81.57 | 90.57 | 10.8 |
Target Audience
- Pharmaceutical & Biotech Companies : Develop market entry strategies, assess competitive positioning, and identify licensing or acquisition opportunities in Europe's high-growth veterinary monoclonal antibodies segment. Critical for R&D investment prioritization and commercial planning.
- Veterinary Healthcare Providers : Understand emerging therapeutic options, treatment adoption trends, and reimbursement landscapes across European markets. Essential for clinical decision-making, practice management, and patient care advancement.
- Investment & Private Equity Firms : Evaluate investment opportunities in European veterinary biotech companies, identify acquisition targets, and assess market growth potential. Supports portfolio strategy and deal sourcing in the high-growth veterinary therapeutics sector.
- Regulatory & Government Bodies : Monitor market trends, assess therapeutic innovation pipelines, and inform policy decisions regarding veterinary drug approvals and animal health regulations. Supports evidence-based regulatory frameworks and public health planning.
- Market Research & Consulting Firms : Access granular European market data to support client advisory services, competitive intelligence, and strategic consulting engagements. Enhances research capabilities and supports client decision-making across veterinary healthcare sectors.
Countries within Europe - compare and drill down
| Country | 2025 size (native) |
|---|---|
| Germany | USD 132.72 Million |
| France | USD 115.27 Million |
| UK | USD 129.58 Million |
| Italy | USD 96.73 Million |
| Spain | USD 83.01 Million |
| Netherlands | USD 51.36 Million |
| Rest Of Europe | USD 81.84 Million |
Country market size visualization
Reasons to Buy this Report
- Country-Level Market Intelligence : Access detailed market sizing and growth projections for Germany, France, UK, Italy, Spain, Netherlands, and Rest of Europe. Understand regional variations in adoption rates, regulatory timelines, and competitive landscapes to optimize market entry strategies.
- Regulatory & Compliance Insights : Gain comprehensive understanding of EMA approval pathways, national regulatory requirements across European markets, and compliance frameworks. Essential for companies navigating Europe's complex veterinary pharmaceutical approval processes.
- Competitive Landscape Analysis : Identify leading players, emerging competitors, and market consolidation trends specific to Europe. Benchmark your position against regional and global competitors with detailed competitive profiling and market share analysis.
- Segment & Application Breakdown : Understand companion animal versus livestock market dynamics, disease indication opportunities, and therapeutic area growth rates. Tailor product development and commercialization strategies to high-growth European segments.
- Strategic Growth Opportunities : Discover untapped market segments, emerging therapeutic areas, and geographic expansion opportunities within Europe. Identify partnerships, acquisition targets, and investment priorities aligned with regional market trends and unmet veterinary needs.
Frequently asked questions
What is the current size of Europe's veterinary monoclonal antibodies market?
Europe's veterinary monoclonal antibodies market is valued at $437.49 million in 2025, reflecting strong demand for advanced immunotherapies across the region's companion and livestock sectors.
What is the projected market size for Europe by 2030?
Europe's veterinary monoclonal antibodies market is forecast to reach $765.31 million by 2030, representing significant expansion driven by regulatory support and therapeutic innovation.
What is the CAGR for Europe's veterinary monoclonal antibodies market?
Europe's veterinary monoclonal antibodies market is expected to grow at an 11.8% compound annual growth rate from 2025 to 2030.
Which countries are leading Europe's veterinary monoclonal antibodies market?
Germany, France, and the United Kingdom are among Europe's leading markets, driven by advanced veterinary infrastructure, high pet ownership, and strong regulatory frameworks supporting biologic adoption.
What factors are driving growth in Europe's veterinary monoclonal antibodies market?
Key growth drivers in Europe include rising pet ownership, increased awareness of precision medicine in veterinary practice, stringent quality standards, established reimbursement pathways, and substantial R&D investment in animal immunotherapies.
RESEARCH METHODOLOGY
This study involved the extensive use of both primary and secondary sources. The research process involved evaluating various factors affecting the industry to identify the segmentation, industry trends, key players, competitive landscape, market dynamics, and growth strategies.
Secondary Research
In the secondary research process, various secondary sources were referred to, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect valuable information for an extensive, technical, market-oriented, and commercial study of the veterinary monoclonal antibodies market. It was also used to obtain information about the key players, market classification & segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various primary sources from the supply and demand sides were interviewed to obtain critical qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, vice presidents, chairpersons, chief executive officers, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the veterinary monoclonal antibodies market. Primary sources from the demand side include professionals from veterinary hospitals and clinics, academic & research institutes, and pet owners.
Breakdown of primary interviews
Note: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.
Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the veterinary monoclonal antibodies market was determined after data triangulation from two approaches, as mentioned below. After each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
Veterinary monoclonal antibodies are laboratory-produced antibodies designed to target specific antigens in animals, offering precise treatment for conditions like atopic dermatitis, osteoarthritis, and infectious diseases. These species-specific biologics are engineered to work effectively in the immune systems of dogs, cats, or livestock. They represent a significant advancement over traditional drugs by providing targeted therapy with fewer side effects.
Stakeholders
- Veterinary monoclonal antibody manufacturers
- Animal healthcare product manufacturers
- Veterinary monoclonal antibody distributors and wholesalers
- Animal welfare associations
- Veterinary clinics and care centers
- Research and consulting firms
- Veterinary R&D organizations
- Contract research organizations
- Contract manufacturing organizations
- Venture capitalists
Report Objectives
- To define, describe, and forecast the veterinary monoclonal antibodies market by animal type, product, therapy area, route of administration, end user, and region
- To identify and analyze key drivers, restraints, opportunities, and challenges influencing market growth
- To strategically analyze the regulatory scenario, value chain analysis, supply chain analysis, Porter’s Five Forces analysis, ecosystem analysis, trade analysis, pricing analysis, patent analysis, impact of AI, case study analysis, adjacent market analysis, unmet needs/end user expectations, and trends and disruptions impacting customer business in the market
- To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze opportunities for stakeholders and provide details of the competitive landscape for key players
- To strategically profile key players in this market and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches and approvals, partnerships, and expansions in the market
Get the Full Veterinary Monoclonal Antibodies Market Report
Full forecast, segment splits, and company analysis for all Veterinary Monoclonal Antibodies Market.
- Canada Veterinary Monoclonal Antibodies Market
- US Veterinary Monoclonal Antibodies Market
- Germany Veterinary Monoclonal Antibodies Market
- France Veterinary Monoclonal Antibodies Market
- UK Veterinary Monoclonal Antibodies Market
- Italy Veterinary Monoclonal Antibodies Market
- Spain Veterinary Monoclonal Antibodies Market
- Netherlands Veterinary Monoclonal Antibodies Market
- Japan Veterinary Monoclonal Antibodies Market
- China Veterinary Monoclonal Antibodies Market
- India Veterinary Monoclonal Antibodies Market
- Australia Veterinary Monoclonal Antibodies Market
- South Korea Veterinary Monoclonal Antibodies Market
- New Zealand Veterinary Monoclonal Antibodies Market
- Brazil Veterinary Monoclonal Antibodies Market
- Mexico Veterinary Monoclonal Antibodies Market
- Rest Of Europe Veterinary Monoclonal Antibodies Market
- Rest Of Asia Pacific Veterinary Monoclonal Antibodies Market
- Rest Of Latin America Veterinary Monoclonal Antibodies Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
